a-192621 and Prostatic-Neoplasms

a-192621 has been researched along with Prostatic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for a-192621 and Prostatic-Neoplasms

Article	Year
Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. The Prostate, 2004, Aug-01, Volume: 60, Issue:3 Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level.. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10(-6)-10(-10) M) and PSA levels were measured in the culture media.. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion.. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines. Topics: Atrasentan; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured	2004

Article

Year

Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines.

The Prostate, 2004, Aug-01, Volume: 60, Issue:3

Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level.. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10(-6)-10(-10) M) and PSA levels were measured in the culture media.. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion.. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

Topics: Atrasentan; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured

2004